Executive Summary
Novo Nordisk presents a compelling investment case as the global leader in GLP-1 therapeutics, commanding 62% volume market share in a category that grew over 30% in 2025. The company reports in Danish Kroner, and proper currency conversion is essential: 2025 revenue of DKK 309 billion translates to approximately $42-43 billion USD, with net income of roughly $14 billion USD and EPS per ADR of approximately $3.15. Operating margins have held above 42% for thirteen consecutive years, gross margins sit at 82%, and ROIC — while declining from its 83% peak in 2015 — still registers 43% on a trailing basis. These are franchise-quality economics sustained across an entire decade of competitive evolution, and they reflect the biologic manufacturing moat that requires $10-15 billion and 8-12 years for any competitor to replicate. At $36.53 per ADR, the stock trades at approximately 11.6x 2024 EPS ($3.15 per ADR from ROIC.AI), having declined roughly 48% from its 2024 highs. The market appears to be pricing in a scenario of permanent competitive erosion and structurally declining returns — embedding perhaps 2-3% perpetual FCF growth for a business that compounded FCF per share at approximately 14% annually over the past five years. Using a blended valuation approach — 15-17x normalized EPS of $3.00-3.15 (yielding $45-54), cross-checked against FCF yield analysis on normalized FCF/share of approximately $2.00-2.20 — the majority arrives at a fair value range of $45-52 per ADR. This implies 23-42% upside from the current price, with downside to approximately $35-38 in a bear scenario where margins compress to 38% and the multiple stays depressed at 12x on $2.90 trough EPS. The risk-reward asymmetry of roughly 3:1 upside-to-downside is compelling, though the magnitude of upside is more modest than the original analysis suggested once we properly account for the balance sheet transformation and competitive dynamics. The investment thesis rests on five independent near-term catalysts: the Wegovy pill commercial ramp (50,000 weekly prescriptions in its first three weeks, though 90% self-pay creates reimbursement uncertainty), the anticipated FDA decision on high-dose semaglutide 7.2mg, CagriSema's FDA submission with a decision expected late 2026 or early 2027, Medicare Part D obesity coverage anticipated for mid-2026, and the REDEFINE 4 head-to-head data against tirzepatide. However, the majority acknowledges genuine risks that the original analysis underweighted. The balance sheet has undergone a dramatic transformation — total debt rose from DKK 27 billion (2023) to DKK 131 billion (2025) while cash collapsed from DKK 16 billion to under DKK 500 million. Free cash flow swung from positive DKK 65 billion in 2023 to negative DKK 8 billion in 2024 before recovering to DKK 40 billion in 2025, driven by massive manufacturing CapEx whose ultimate returns remain unproven. Management's own earnings call language — citing states dropping Medicaid obesity coverage and lower realized prices across multiple products — signals pricing and reimbursement headwinds that could limit the volume-for-price trade-off the bulls depend upon. The majority recommends beginning to accumulate shares at current levels with disciplined position sizing of 2-3% of portfolio, recognizing that the balance sheet leverage and competitive transition introduce more uncertainty than a typical franchise pharmaceutical investment. The conviction is tempered by the fact that this is a business in the midst of the largest investment cycle in its century-long history, with two C-suite departures, a new CEO seven months into the role, and a 9,000-person restructuring — execution risk is elevated precisely when it matters most.
The minority holds that Novo Nordisk fails critical qualitative filters regardless of its current valuation. Kantesaria categorically excludes healthcare and pharma from his investable universe because clinical outcomes over 5-10 year horizons are inherently unpredictable — the emergence of Eli Lilly's tirzepatide as a clinically superior molecule within three years of semaglutide's dominance vindicates this position. The moat in pharmaceuticals is R&D-dependent, requiring constant reinvention rather than compounding automatically. Compare this to Kantesaria's actual holdings — FICO, Moody's, Visa — where competitive advantages are structural, self-reinforcing, and inevitable. There is no pharmaceutical equivalent of 'every mortgage requires a FICO score.' A physician's prescription is a choice that can shift with a single clinical trial readout. Prasad applies his Darwinian survival framework and concludes that the rate of competitive change in GLP-1 therapeutics — from a monopoly to a broadening oligopoly with 100+ molecules in development in under five years — represents exactly the fast-changing environment where moats erode and evolutionary fitness is tested quarterly. The ROIC trajectory from 83% (2015) to 43% (TTM) across fourteen years is the financial signature of a business whose competitive advantages are compressing, not compounding. The balance sheet transformation from DKK 27 billion to DKK 131 billion in debt — converting a fortress into a leveraged bet on manufacturing capacity whose returns are unproven — amplifies rather than mitigates this structural risk. Both minority members acknowledge the exceptional current economics but argue they are the output of a temporary competitive position, not a durable structural advantage. Pabrai recognizes the exceptional business quality but is constrained by the $162 billion market cap, which mathematically prevents the 3:1 asymmetric returns his framework requires. A triple from here would imply approximately $490 billion — roughly 35x current earnings — which requires assumptions he is unwilling to make. He would eagerly reconsider at $18-20 per ADR ($80-90 billion market cap) where the franchise quality and the asymmetric math align.